"Designing Growth Strategies is in our DNA"

Enzyme Replacement Therapy Market Size, Share & Industry Analysis, By Drug Class (Alglucosidase alfa, Agalsidase, Pancrelipase, Idursulfase, Laronidase, Imiglucerase, Elosulfase alfa, Asfotasealfa, Galsulfase, Velaglucerase alfa, and Others), By Route of Administration (Parenteral and Oral), By Indication (Type 1 Gaucher Disease, Pompe Disease, MPS (Mucopolysaccharidosis), Exocrine Pancreatic Insufficiency (EPI), Fabry Disease, Hypophosphatasia, and Others), By End User (Hospitals and Homecare Settings & Infusion Centers), and Regional Forecast, 2024-2032

Last Updated: April 28, 2025 | Format: PDF | Report ID: FBI106424

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of  9.2% from 2024-2032

Unit

Value (USD Billion)

Segmentation    

By Drug Class

  • Alglucosidase alfa
  • Agalsidase
  • Pancrelipase
  • Idursulfase
  • Laronidase
  • Imiglucerase
  • Elosulfase alfa
  • Asfotase alfa
  • Galsulfase
  • Velaglucerase alfa
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Indication

  • Type 1 Gaucher disease
  • Pompe Disease
  • MPS (Mucopolysaccharidosis)
  • Exocrine Pancreatic Insufficiency (EPI)
  • Fabry Disease
  • Hypophosphatasia
  • Others

By End User

  • Hospitals
  • Homecare settings & Infusion Centers

By Geography

  • North America (By Drug Class, By Route of Administration, By Indication, By End User, and By Country)
    • U.S. (By Indication)
    • Canada (By Indication)
  • Europe (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
    • U.K. (By Indication)
    • Germany (By Indication)
    • France (By Indication)
    • Italy (By Indication)
    • Spain (By Indication)
    • Scandinavia (By Indication)
    • Rest of Europe (By Indication)
  • Asia Pacific (By Drug Class, By Route of Administration, By Indication, By End User, and By Country/Sub-region)
    • Japan (By Indication)
    • China (By Indication)
    • India (By Indication)
    • Australia (By Indication)
    • Southeast Asia (By Indication)
    • Rest of Asia Pacific (By Indication)
  • Latin America (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
    • Brazil (By Indication)
    • Mexico (By Indication)
    • Rest of Latin America (By Indication)
  • Middle East& Africa (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
    • South Africa (By Indication)
    • GCC (By Indication)
    • Rest of Middle East & Africa (By Indication)
  • 2019-2032
  • 2023
  • 2019-2022
  • 150
GET A FREE SAMPLE
    The free sample includes data points such as market estimates, growth rate, size of the largest region and segment of the market.
Consulting Services
    How will you benefit from our consulting services ?